James Zweibel

483 citations
10 papers · 370 indexed · h-index 8
Topics
Histone Deacetylase Inhibitors Research (6 papers)Protein Degradation and Inhibitors (5 papers)Multiple Myeloma Research and Treatments (2 papers)

In The Last Decade

James Zweibel

10 papers receiving 362 citations

Peers

James Zweibel
Comparison fields: 5 of 66
  • Molecular Biology 258
  • Oncology 123
  • Cancer Research 70
  • Endocrinology, Diabetes and Metabolism 40
  • Pulmonary and Respiratory Medicine 39
Replace Yangxin Fu with:
Yangxin Fu Canada
Janet Mendonca United States
Thomas A. Lampkin United States
A. Seun Ajiboye United States
Jinrong Cheng United States
Touko Inao Japan
Carolina Castilla Spain
W. Roy Smythe United States
Mohammed Benkheil Belgium
Mark Edelstein United States
James Zweibel relative to Yangxin Fu Canada Yangxin Fu's profile →
Citations per field
00.5×
Yangxin Fu · 1×
Citations per year

Countries citing papers authored by James Zweibel

Since Specialization
Citations

This map shows the geographic impact of James Zweibel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Zweibel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Zweibel more than expected).

Fields of papers citing papers by James Zweibel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Zweibel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Zweibel. The network helps show where James Zweibel may publish in the future.

Co-authorship network of co-authors of James Zweibel

This figure shows the co-authorship network connecting the top 25 collaborators of James Zweibel. A scholar is included among the top collaborators of James Zweibel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Zweibel. James Zweibel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
#WorkIndexed citations
1 2
2 11
3 47
4 189
5 17
6 22
7 9
8 2
9 17
10 54

About James Zweibel

James Zweibel is a scholar working on Cancer Research, Gastroenterology and Hematology, having authored 10 papers that have together received 370 indexed citations. Recurring topics across this work include Histone Deacetylase Inhibitors Research (6 papers), Protein Degradation and Inhibitors (5 papers) and Multiple Myeloma Research and Treatments (2 papers). The work is most often cited by research in Cancer Research (70 citations), Oncology (123 citations) and Molecular Biology (258 citations). James Zweibel has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include James R. Wright, James H. Doroshow, Helen X. Chen, Susan L. Holbeck, Joseph E. Tomaszewski, Jerry M. Collins, Audrey Rasmussen, Brett Leav, Kevin J. Cullen and Zhi-Zheng Yang. Their work appears in journals such as Journal of Clinical Oncology, Blood and Nature Reviews Drug Discovery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026